Holen Sie sich die Stockscreener-App
132.59
0.45%
0.59
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$132.00
Offen:
$132.77
24-Stunden-Volumen:
4.13M
Relative Volume:
0.64
Marktkapitalisierung:
$230.77B
Einnahmen:
$43.11B
Nettoeinkommen (Verlust:
$13.94B
KGV:
16.62
EPS:
7.98
Netto-Cashflow:
$6.78B
1W Leistung:
+0.64%
1M Leistung:
+5.46%
6M Leistung:
-1.73%
1J Leistung:
+18.28%
1-Tages-Spanne:
$131.34
$133.62
1-Wochen-Bereich:
$128.68
$133.81
52-Wochen-Spanne:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Vergleichen Sie ABT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Top Research Reports for Amazon.com, Salesforce & Abbott - MSN
Abbott Sues Chinese Rival Over Glucose Monitor UK Patent - Law360
Abbott Gets $7 Million Shaved From Tax Value of Minnesota Lab - news.bloombergtax.com
Should You Invest in Abbott (ABT) Based on Bullish Wall Street Views? - Yahoo Finance
Abbott gets 2nd formula lawsuit dismissed, spelling trouble for 700 cases - Crain's Chicago Business
Precision Trading with Abbott Laboratories (ABT) Risk Zones - news.stocktradersdaily.com
Stock Analysis | Abbott Laboratories OutlookMixed Signals Amid Fundamental Strength - AInvest
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Alcohol assay from Carolina Liquid Chemistries receives CLIA moderate complexity categorization on Abbott ImmTox™ 270 chemistry analyzer - News-Medical
1 Cash-Producing Stock for Long-Term Investors and 2 We Question - FinancialContent
Synlait mum on rumoured US buyer for 'cash burning' Pōkeno plant - ThePost.co.nz
Abbott Shares Slide 1.12% as Trading Volume Dives 43.81% to 182nd Rank Amid Blood Campaign Push - AInvest
Abbott Laboratories scores a win in federal court, as it faces hundreds of suits over formula for preterm babies - Chicago Tribune
Here's Why We Think Abbott Laboratories (NYSE:ABT) Is Well Worth Watching - 富途牛牛
$1 Million Prize: Abbott and Big Ten's Massive Blood Drive Competition Returns After 12,000 Lives Saved - Stock Titan
Abbott Gains in Nutrition With Adult Segment Leading Growth - Yahoo Finance
Abbott Laboratories (NYSE:ABT) Could Easily Take On More Debt - Yahoo Finance
Synlait to sell plant to Abbott Labs as a2 Milk buys asset from rival - The Australian
Abbott Laboratories Sheds 8% On A Rare Guidance Miss - MSN
How Abbott Laboratories (ABT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
What is the target price for Abbott Laboratories stockWeekly Risk Report & Growth Focused Investment Plans - thegnnews.com
Insider Sales: D-Wave, AGNC, BigBearai, Abbott, Etsy - TipRanks
2 Stocks to Buy on the Dip and Hold for 10 Years - The Motley Fool
EXPERT EVIDENCE—BABY PRODUCTS—N.D. Ill.: Expert’s testimony did not apply to preterm infant; Abbott Labs thus entitled to summary judgment in baby formula litigation - VitalLaw.com
Abbott Laboratories (NYSE:ABT) Q2 2025 Earnings Call Transcript - MSN
How Abbott Laboratories stock performs during market volatilityJuly 2025 Outlook & Reliable Price Breakout Signals - thegnnews.com
Abbott Shares Dip Despite Record Volume Surge and FDA Approval Targets 20 CAGR Market Ranks 57th in Daily Trading Activity - AInvest
Abbott Taps Growing TMVR Market With Tendyne System - The Globe and Mail
Does Abbott Laboratories (NYSE:ABT) Deserve A Spot On Your Watchlist? - Yahoo Finance
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT) - msn.com
Saudi Arabia Blood Glucose Device Market Trends and Company - GlobeNewswire
Saudi Arabia Blood Glucose Device Market Trends and Company Analysis Report 2025-2033 Featuring Abbott Laboratories, Medtronic, Dexcom, Braun, DarioHealth, Sanofi, Bionime, and Novo Nordisk - Yahoo Finance
Chris Blumas' Past Picks: Brookfield Corp, Abbott Labs & Great-West Lifeco - BNN Bloomberg
United States Epilepsy Drugs Market Trends and Company - GlobeNewswire
United States Epilepsy Drugs Market Trends and Company Analysis Report 2025-2033 Featuring Eisai, UCB, H. Lundbeck, GW Pharmaceuticals, Abbott, Alkem Laboratories, Bausch Health, GSK - Yahoo Finance
US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche - Yahoo Finance
Abbott India's profit climbs on healthy pharmaceutical demand - Reuters
Top Abbott Executive Makes Significant Stock Sale! - TipRanks
Abbott Plummets 2.17% Amid Regulatory Scrutiny as Volume Surges 40.74% to 940M Ranking 93rd - AInvest
Abbott Shakes Suit Over Meta, Google Data Sharing For Now - Law360
Abbott Laboratories EVP and CFO Sells 5,550 Shares at $134.55/Share on August 8, 2023. - AInvest
Abbott Laboratories poised to end in red after six-session rally - MSN
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Abbott Laboratories Faces Correction Amid Six-Session Rally - AInvest
Abbott Labs Beats Class Action Over Meta, Google Info Sharing - Bloomberg Government News
Abbott Laboratories shows growth in core products amid market shifts - Yahoo Finance
Are Wall Street Analysts Predicting Abbott Laboratories Stock Will Climb or Sink? - Yahoo Finance
Abbott Laboratories maintains steady performance amid market shifts - Express Healthcare
Abbott Laboratories (NYSE:ABT) jumps 5.5% this week, though earnings growth is still tracking behind five-year shareholder returns - Yahoo Finance
Abbott's EPD Growth Beats Market Trends: Here's How to Play the Stock - MSN
Abbott Laboratories Q2 Earnings: Dividends Don’t Lie (NYSE:ABT) - Seeking Alpha
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):